Dialybrid Raises €15 Million in Series A Funding
Dialybrid, an Italian medical device company specializing in innovative solutions for hemodialysis, has successfully raised €15 million in a Series A funding round. The funding was led by XGEN Venture, with additional investment from CDP Venture Capital.
Focus on Silkothane® Technology
Dialybrid is focused on developing the Silkothane® Arteriovenous Graft, a novel hybrid material that combines silk fibroin and polyurethane. This technology aims to provide a durable and easy-to-use vascular access for patients undergoing hemodialysis, particularly those with end-stage kidney disease.
Clinical Developments
The company has recently achieved a milestone with the first successful human implant of the Silkothane® Graft in a pilot clinical trial in Italy. The trial is being led by Professor Matteo Tozzi, MD, Director of the Vascular Surgery Department at ASST Sette Laghi and a Professor of Vascular Surgery at Insubria University.
Use of Funds
The newly acquired funds will be directed towards the clinical development of Dialybrid’s Silkothane® Arteriovenous Graft. Additionally, the company plans to explore other vascular applications for the Silkothane® material.
Leadership and Vision
Francesco Greco, Founder and CEO of Dialybrid, is at the helm of the company, guiding its strategic direction and clinical initiatives.
Upcoming Presentation
Dialybrid is set to present at the LSI Europe '26 Emerging Medtech Summit on September 29, 2026, further showcasing its innovative solutions in the medical technology space.